Type 2 diabetes (T2DM) is closely associated with obesity. Given that weight loss is associated with T2DM remission,1 there has been intense interest in diabetes outcomes following bariatric surgery. The landmark Surgical Therapy and Medications Potentially Eradicate Diabetes Efficiently (STAMPEDE) trial found that bariatric surgery was a more effective diabetes treatment compared with medical management after 5 years of follow-up.1 While it was not adequately powered to detect differences between Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG), other randomized clinical trials have found no differences in diabetes resolution between RYGB and SG.2,3
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Liu N, Funk LM. Bariatric Surgery and Diabetes Treatment—Finding the Sweet Spot. JAMA Surg. Published online March 04, 2020. doi:10.1001/jamasurg.2020.0088
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: